Rain Oncology
8000 Jarvis Ave Suite 204
Newark
CA
94560
United States
Tel: 510-953-5559
Website: https://www.rainoncology.com/
Email: info@rainoncology.com
About Rain Oncology
Rain BRINGS LIFE
The beauty and complexity of life is near limitless, with the world around us based on the cyclicality of the seasons and marking a shift in the progression of life. When the rains come, they bring sustenance to the life all around us, from which there is renewal and replenishment. Water and the rain help reinvigorate life and strengthen us for the path forward.
Rain Oncology was named to symbolize the renewal, sustenance and replenishment that reinvigorates life afforded by the rains. In the same way, we hope to provide a renewal and reinvigoration for patients debilitated by cancer. Rain Oncology hopes to leverage industry-leading insight into the mechanisms triggering cancer to find precision therapeutic strategies that may offer patients an improved chance of getting their lives back.
Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic success for patients by focusing on genetic biomarkers that may predict optimal therapeutic strategies, and (2) pursue biomarker-based trial designs of limited size that enable rapid decision-making and redirecting of strategy when needed, minimizing expense and preserving capital resources.
Our team is the heart and soul of Rain Oncology. Not only is a dynamic, energetic, entrepreneurial team essential to drug development success at Rain, it's also paramount to the type of culture where people feel rewarded every day.
Rain Oncology is looking for team members that don't want to work in a conventional corporate environment. We are looking for professionals who believe, at their core, that a small company that empowers its people can move much more quickly and effectively than large organizations with significantly more financial firepower. Rain Oncology is looking for experts who want more control in galvanizing 21st-century science for patients.
Stock Symbol: RAIN
45 articles about Rain Oncology
-
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Rain Oncology Inc. reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.
-
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
10/16/2023
Rain Oncology, Inc. confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.
-
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/10/2023
Rain Oncology Inc., reports financial results for the second quarter ended June 30, 2023, and provides a corporate update.
-
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
7/26/2023
Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023.
-
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
5/30/2023
Rain Oncology Inc., a clinical stage company developing precision oncology therapeutics announced an update to its clinical strategy for milademetan, its small molecule inhibitor of the MDM2-p53 complex, to optimize Company resources.
-
Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium
11/23/2022
Rain Therapeutics Inc. today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.
-
Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
11/18/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler’s 34th Annual Healthcare Conference.
-
Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference
11/14/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022.
-
Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
11/10/2022
Rain Therapeutics Inc. reported financial results for the third quarter ended September 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.
-
Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
11/4/2022
Rain Therapeutics Inc. today announced preliminary data in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors.
-
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
10/27/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022.
-
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium
10/26/2022
Rain Therapeutics Inc. announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.
-
BioSpace spoke with three CEOs: Alto Neuroscience’s Dr. Amit Etkin, Omega Therapeutics’ Mahesh Karande and Rain Therapeutics’ Avanish Vellanki about their companies' employment growth.
-
Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
8/31/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.
-
UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
8/4/2022
Rain Therapeutics Inc. announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.
-
Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
8/4/2022
Rain Therapeutics Inc., a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.
-
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
8/4/2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.
-
In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, milademetan, and a pivotal readout for its Phase III trial of the same compound.
-
Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress
5/4/2022
Rain Therapeutics Inc. reports financial results for the first quarter ended March 31, 2022, along with an update on the Company's key developments, business operations and upcoming milestones.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.